ANAVEX LIFE SCIENCES CORP. Net Cash Provided by (Used in) Financing Activities, Continuing Operations
ANAVEX LIFE SCIENCES CORP. (AVXL) reported Net Cash Provided by (Used in) Financing Activities, Continuing Operations of $22.43 million for the 9-month period ending 2017-06-30, per its 10-Q filed 2017-08-07.
Discontinued › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations · last filed 2017-08-07
- ANAVEX LIFE SCIENCES CORP. net cash provided by (used in) financing activities, continuing operations for the quarter ending 2017-06-30 was $4.42M.
- ANAVEX LIFE SCIENCES CORP. net cash provided by (used in) financing activities, continuing operations for the quarter ending 2017-03-31 was $2.89M.
- ANAVEX LIFE SCIENCES CORP. net cash provided by (used in) financing activities, continuing operations for the quarter ending 2016-12-31 was $15.13M, a 735.99% increase year-over-year.
- ANAVEX LIFE SCIENCES CORP. net cash provided by (used in) financing activities, continuing operations for the quarter ending 2016-09-30 was $1.32M, a 84.90% decline year-over-year.
- ANAVEX LIFE SCIENCES CORP. net cash provided by (used in) financing activities, continuing operations for fiscal 2016 was $3.13M, a 74.44% decline from fiscal 2015.
- ANAVEX LIFE SCIENCES CORP. net cash provided by (used in) financing activities, continuing operations for fiscal 2015 was $12.26M, a 27.94% increase from fiscal 2014.
- ANAVEX LIFE SCIENCES CORP. net cash provided by (used in) financing activities, continuing operations for fiscal 2014 was $9.58M.
| Period end | Net Cash Provided by (Used in) Financing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Financing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Financing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Financing Activities, Continuing Operations 12 month |
|---|---|---|---|---|
| 2017-06-30 | $4.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-08-07 | $7.30M derived: sum of 2 quarters · filed 2017-08-07 | $22.43M 10-Q · filed 2017-08-07 | $23.75M derived: sum of 4 quarters · filed 2017-08-07 |
| 2017-03-31 | $2.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-05-10 | $18.02M 10-Q · filed 2017-05-10 | $19.34M derived: sum of 3 quarters · filed 2017-05-10 | $19.34M derived: sum of 4 quarters · filed 2017-08-07 |
| 2016-12-31 | $15.13M 10-Q · filed 2017-02-07 | $16.45M derived: sum of 2 quarters · filed 2017-02-07 | $16.45M derived: sum of 3 quarters · filed 2017-08-07 | $16.45M derived: sum of 4 quarters · filed 2017-08-07 |
| 2016-09-30 | $1.32M derived: 10-K 12 month − 10-Q 9 month · filed 2016-12-14 | $1.32M derived: sum of 2 quarters · filed 2017-08-07 | $1.32M derived: sum of 3 quarters · filed 2017-08-07 | $3.13M 10-K · filed 2016-12-14 |
| 2016-06-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-08-07 | -$1.00 derived: sum of 2 quarters · filed 2017-08-07 | $1.81M 10-Q · filed 2017-08-07 | $10.57M derived: sum of 4 quarters · filed 2017-08-07 |
| 2016-03-31 | -$1.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-05-10 | $1.81M 10-Q · filed 2017-05-10 | $10.57M derived: sum of 3 quarters · filed 2017-05-10 | $13.65M derived: sum of 4 quarters · filed 2017-05-10 |
| 2015-12-31 | $1.81M 10-Q · filed 2017-02-07 | $10.57M derived: sum of 2 quarters · filed 2017-02-07 | $13.65M derived: sum of 3 quarters · filed 2017-02-07 | $13.65M derived: sum of 4 quarters · filed 2017-02-07 |
| 2015-09-30 | $8.76M derived: 10-K 12 month − 10-Q 9 month · filed 2016-12-14 | $11.84M derived: sum of 2 quarters · filed 2016-12-14 | $11.84M derived: sum of 3 quarters · filed 2016-12-14 | $12.26M 10-K · filed 2016-12-14 |
| 2015-06-30 | $3.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-08-11 | $3.08M derived: sum of 2 quarters · filed 2016-08-11 | $3.49M 10-Q · filed 2016-08-11 | |
| 2015-03-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-05-11 | $411.86K 10-Q · filed 2016-05-11 | ||
| 2014-12-31 | $411.86K 10-Q · filed 2016-02-08 | |||
| 2014-09-30 | $9.58M 10-K · filed 2016-12-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |